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Abstract 
Background: Leishmania major LmSTI1 is a conserved protein among different species of leishmania, and 
expressed in both amastigote and promastigote forms of L. major life cycle. It has previously been expressed in 
bacterial systems. 
Materials and Methods: To express LmSTI1 in the methylotrophic yeast Pichia pastoris (P. pastoris), the 
shuttle vector pPICZA containing gene lmsti1 was constructed under the control of the AOX1 promoter. The 
recombinant vector was electro-transformed into P. pastoris, and induced by 0.5% methanol in the buffered 
medium. The expression of the LmSTI1 protein was visualized in the total soluble protein of P. pastoris by 
12% SDS-PAGE, and further confirmed by Western blotting with L.major-infected mouse sera and HRP-
conjugated goat anti-mouse IgG as the first and secondary antibodies, respectively. 
Results: The expression level was 0.2% of total soluble proteins. 
Conclusion: It might be possible to use this formulation as a whole yeast candidate vaccine against cutaneous 
leishmanization. 
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Leishmaniasis is an endemic disease, ranging from 
localized cutaneous to visceral forms. Cutaneous 
leishmaniasis is caused by different leishmania 
parasites including leishmania major (L.major) , L. 
tropica, L. aethiopica, L. mexicana, L. guyanensis, L. 
peruviana, and L. braziliensi
1,2
. According to WHO 
estimation, the annual incidence of leishmaniasis in 
new cases is about 2 million people worldwide, most 
of which (1.5 million) suffer from cutaneous 
leishmaniasis (http://www.who.org).  
Leishmaniasis is primarily mediated by T 
lymphocytes. To neutralize intracellular parasitic 
infections such as leishmania, cellular immunity was 
demonstrated to play a critical role in inducing 
protective immunity
3
. In mouse models of leishmania 
infection, the Th1 response phenotype is observed in 
protected animals such as C57BL/6 mice by increasing 
IFN-gamma and TNF-alpha while the Th2 response 
phenotype producing IL-4 and IL-5 is associated with 
susceptibility or disease progression
4-6
. In the 
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susceptible BALB/c mice, immunization elicited Th1 
responses and established resistance to L. major (7, 
8), so that each protective vaccine should be able to 
induce broad and intense Th1 Tcell responses.  
Antigen presenting cells (APCs) are one of the most 
important cells in Th1 responses. APCs, mostly 
dendritic cells (DCs), by producing IL-12 increase 
the activity of different effectors including T cells, 
natural killer cells and macrophages in early stages of 
leishmaniasis
9
. In addition, DCs are able to 
differentiate responses into producing Th1 cells. In 
contrast, Th2 lymphocytes lead T cells to producing 
anti-leishmania cytokines such as IFN-γ
10,11
. 
Furthermore, these cells have a key role in 
stimulating cytotoxic T lymphocytes in a process, 
known as cross-presentation (12). On this subject, 
DCs can both endocytosis and process exogenous 
antigens, present molecules to CD8+ T cells 
(cytotoxic T cells) through the major 
histocompatibility complex (MHC) class I pathway, 
and activate naive antigen-specific CD8+ T cells
13
. 
L. major stress-inducible protein 1 (LmSTI1) is a heat 
shock protein expressed in both amastigote and 
promastigote forms of L. major
14
. In a study, 
CAMPOS-NETO et al. found that LmSTI1 and TSA 
plus IL-12 were able to induce protection against 
cutaneous leishmaniasis in both murine and 
nonhuman primate models with the strong response 
of Th1 and higher amounts of interferon gamma; 
however, the amount of cytokine produced by 
LmSTI1 was much more than that of TSA
15
. In the 
other study, vaccination by using protein LmSTI1 
and liposome with sequences containing CpG, as an 
adjuvant, high proportion of IgG2a/ IgG1 and 
efficient protection in mice were observed up to 14 
weeks after challenge
16
. On the other hand, studies 
on vaccines that has reached the stage of trial 
(Leish111-f) represent the strongest antibody 
response and highest IF-γ in vaccinated mice with 
LmSTI1 compared to other vaccine components 
(TSA, and LeIF)
17
. Above all, lmSTI1 alone can 
elicit robust protective immunity by as much as 
compositions of protein antigens with each other, 
making this protein a good candidate for the design 
of vaccines against cutaneous leishmaniasis. 
The use of whole recombinant yeast vaccines is 
considered as a novel approach to induce protective 
immunity in cancer and infectious diseases
18,19
. This 
system offers several advantages over conventional 
methods for vaccine development. Because of the 
intrinsic adjuvant properties of yeast cell walls, 
efficient presentation of both MHC class I and II, the 
ability to express multiple antigens together, safety, 
ease of handling and low cost of mass production, 
yeast is considered as the best strategy to construct a 
vector for vaccine application
20-22
. Importantly, several 
previous studies showed that internalized whole yeast 
by macrophages and dendritic cells (DCs) induces DC 
maturation and IL-12 expression
20,23,24
. In the present 
study, we constructed whole recombinant yeast 
capable of expressing LmSTI1 in the yeast Pichia 
pastoris (P. pastoris) strain x33 as a model system for 
potential application in vaccine studies against 
leishmaniasis. 
Methods 
Parasite culture: The L. major strain 
MRHO/IR/75/ER (Iran vaccine strain, kindly provided 
by Dr. Javadian, School of Public Health, Tehran 
University of Medical Sciences) was cultured in RPMI 
1640 medium supplemented with 10% heat-
inactivated fetal calf serum with 100 U/ml penicillin 
and 100 μg/ml streptomycin, and grown to the mid-
logarithmic phase (approximately 10 million parasites) 
at 24°C. Parasites were then harvested by 
centrifugation (4000 RPM for 10min at 4°C), and 
stored at -20°C.  
DNA extraction: Genomic DNA was extracted as 
described by Kelly (25). Briefly, the frozen parasites 
were thawed and resuspended in 1ml of sterile lysis 
buffer (125 mMNaCl, 125 mM EDTA, 2.5% w/v 
(SDS), 125 mMTris, pH 8.0) containing 100 μg/ml 
proteinase K (Sigma-Aldrich). Subsequently, the DNA 
was extracted by phenol/chloroform and ethanol 
precipitation. The extracted DNA was dissolved in 100 
µl of distilled water and stored at -20°C. 
Construction of expression vector: The full-length 
lmsti1 gene (1641base pairs; a 62.1 KDa ORF) was 
amplified from the extracted genomic DNA using 
following sets of PCR primers (LM and LR in Table 
1). The 5'oligonucleotide primers contain a BamHI 
restriction site (boldface) preceding the ATG initiation 
codon (underlined) followed by sequences derived 
from the first seven amino-acid residues of LmSTI1. 
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The 3'oligonucleotides contain an EcoRI restriction 
site (boldface) immediately followed by the 
termination codon (underlined) and sequences 
comprising the last seven amino acid residues of 
LmSTI1. For long-term storage of the lmsti1 gene, the 
resulting PCR amplicons were digested with BamHI 
and EcoRI enzymes, ligated into the similarly-
digested pUC18 vector and then transformed into 
competent E. coli cells. Ampicilin-resistant 
transformants were identified by restriction analysis, 
and the sequence fidelity was confirmed by 
sequencing. The second PCR primers were designed 
(PLM-F and PLM-R in table 1) to introduce a yeast 
kozak sequence (underlined) and EcoRI (boldface) in 
the forward primer at the N-terminal of the lmsti1 
gene and KpnI restriction site (boldface), without 
termination codon in the reverse primer at the C- 
terminal of the gene sequence. The latter PCR 
product and pPICZA vectors were digested with 
EcoRI and KpnI, ligated and then transformed into 
DH5α competent cells. Ampicilin-resistant 
transformants were identified by restriction analysis, 
and the sequence fidelity was confirmed by 
sequencing. In this strategy of cloning, the 
recombinant plasmid (pPICZA_LmSTI1) was 
constructed (figure 1) by inserting gene lmsti1 in 
frame with 6×His-tag and under the control of the 
strong promoter AOX1, allowing the high expression 
level of the protein by methanol induction.  
Transformation of the recombinant pPICZA into 
P. pastoris: To intergrate the recombinant pPICZA-
LmSTI1 plasmid into the P. pastoris genome, 10 μg 
of recombinant plasmids were linearized by sacI, 
cutting the 5’ AOX (alcohol oxidase) region of the 
plasmid, followed by electroporation into P.  pastoris 
according to supplier’s instructions (Easy Select 
Pichia Expression manual, Invitrogen). Briefly, a 
single colony of P. pastoris strain x33 
(INVITROGEN, CA, USA) grown on YPD (1% 
yeast extract, 2% peptone and 2% dextrose) agar 
plates was transferred into 5 ml of YPD medium in a 
50-ml Erlenmeyer flask overnight at 28°c with 
shaking at 250 rpm. Subsequently, 500 μl of the 
overnight culture was inoculated into 50 ml of fresh 
YPD medium in a 1-liter flask and grown overnight 
again under the same conditions until reaching an 
OD600 of 1.3-1.5. The cells were then centrifuged at 
1500g for 5 min at 4°C, and washed two times with 50 
ml ice-cold sterile water and once with 20 ml ice-cold 
1M sorbitol. The 5–10 μg of linearized recombinant 
plasmids was mixed with 80 μl of competent X33 
cells. The mixture was immediately transferred into a 
pre-chilled 0.2 cm electroporation cuvette and 
incubated on ice for 5 min prior to electroporation on a 
gene pulser (Biorad, USA). Electroporation was 
performed at 1.5 kV, 25 µF and 200 Ω. Approximately 
1 ml ice-cold 1M sorbitol was immediately added to 
the cuvette after electroporation. Subsequently, the 
electroporated cells were plated on the YPD agar 
plates containing Zeocin (500 μg/ml) and incubated 
for 3-7 days at 28°c. Individual transformant colonies 
were then picked from the plates and screened on MD 
(Minimal Dextrose Medium; 1.34% YNB, 4 × 10
-5
% 
biotin, 2% dextrose) agar plates during 2-3 days to 
confirm the mut
+
 phenotype of the X-33 
(INVITROGEN, EasySelect Pichia Expression Kit). 
To screen the integration of the expression cassette 
into the P. pastoris genome, DNA from 10 Zeocin-
resistant colonies were extracted by the method 
described by Hanna et al  (26), and then PCR using 
5'AOX1 and 3'AOX1 primers was performed 
following the standard protocol.  
Expression and extraction of LmSTI1 protein: The 
expression of the LmSTI1 protein was performed 
according to the standard protocols. In this regard, a 
single colony from ten transformants was picked and 
grown overnight at 30C in 5 ml of YPD medium + 
100 μg/ml of Zeocin in a shake flask until the OD600: 
2-3. The cells were then inoculated in 50 ml BMGY 
media (Buffered Glycerol-complex Medium; 1% yeast 
extract, 2% peptone, 100 mM potassium phosphate, 
pH 6.0, 1.34% YNB, 4 × 10
-5
% biotin, 1% glycerol), 
and incubated for one more night until OD600: 2-10. 
The cell pellets were then harvested by centrifugation 
(3500 g, 5 minutes, at RT) and resuspended in the 
same volume of BMMY induction medium (Buffered 
Methanol-complex Medium; 1% yeast extract, 2% 
peptone, 100 mM potassium phosphate, pH 6.0, 1.34% 
YNB, 4 × 10
-5
% biotin, 0.5% methanol), for 3-5 days 
under the same conditions. During the induction 
period, sterile 100% methanol to a final concentration 
of 0.5% was added daily to the cultures. Afterward, 5 
ml of cultures were harvested by centrifugation at 
6000 rpm for 5min at 4C, and the cell pellets were 
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stored at -80C for the expression analysis.  
SDS PAGE and Western Blotting: Cell pellets 
were thawed quickly, placed on ice and then 
resuspended by adding an equal volume of the 
breaking buffer (50 mM sodium phosphate, pH 7.4, 1 
mM PMSF [phenylmethylsulfonyl fluoride or other 
protease inhibitors], 1 mM EDTA, 5% glycerol) and 
glass beads (equal amounts of  150-212 μm and 710-
1,180 μm). The cells were disrupted by vortexing 8 
times for 30 seconds, with 30-second intervals of 
incubation on ice. The disrupted cells were then 
centrifuged for 5–10 minutes at 12,000 × g at 4°C, 
and the clear supernatants were then transferred into 
fresh containers. To analyze the protein expression, 
10µl of each supernatant was resolved by the 
standard Laemmli SDS-PAGE (12%) method 
27
, and 
then visualized by Coomassie Brilliant Blue staining. 
Expression of the LmSTI1 protein was confirmed by 
Western Blotting according to standard protocols; in 
brief, the protein bands were transferred into a 
polyvinylidene difluoride membrane (Sigma-
Aldrich) by electroblotting at 350 mA for 90 min. 
The membrane was then probed with mouse sera (at 
1:100 dilution) containing a high titter of antibodies 
against the LmSTI1 protein (data not shown), as a 
primary antibody, and further incubated with HRP-
conjugated mouse anti IgG (Sigma-Aldrich) for 1h as 
a secondary antibody, followed by developing with 
diaminobenzidine (DAB) (Roche, Switzerland) as a 
substrate. Immediately after visualization, the 
membrane was rinsed with PBS to stop reaction. 
Results 
The whole genomic DNA of L.major was extracted 
from about ten million parasites using the salting-out 
procedure. The full-length lmsti1 gene (1641bp) was 
successfully amplified by the first PCR with LM-F and 
LM-R primers (Figure 2). The first PCR amplicon was 
confirmed by sequencing, and inserted into the PUC18 
vector to maintain the lmsti1 gene as a template (data 
not shown). 
Since the kozak sequence is required for high-
throughput protein expression in the yeast expression 
Table 1: Primers used for cloning of LmSTI1 into pUC18 (LM-F and LM-R) and pPICZA (PLM-F and PLM-R). 
primers Sequences 
LM-F 5’-A-GGA-TCC-ATG- A -  A-A  - A -   -AA -  
LM-R  5’-T-GAA-TTC-CTA-   -A  -AAA-A  -AA - A -   -  
PLM-F 5’-AGA-GAA-TTC-GAC-ATG-GA -  A-A  - A -   -  




Figure 1. Schematic diagram of the pPICZA vector harboring 
lmsti1 gene. lmsti1 gene was cloned into the pPICZA vector via 
EcoRI and KpnI sites in frame with 6×His, downstream of 
5’AOX1 promoter. AOX1 TT, 6xHis and Stop indicate to the 





Figure 2. Agarose gel electrophoresis of the full length lmsti1 
amplicon. Genomic DNA of L.major was extracted and then 
amplified by the first PCR reaction. Lane 1: full length of lmsti1 
gene; Lane M: DNA 1 Kb ladder. 
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system, an additional PCR reaction was performed to 
add this sequence to the upstream of the gene lmsti1, 
and the PCR amplicon was then inserted into the 
pPICZA vector. The new recombinant vector, 
pPICZA-LmSTI1, was confirmed by restriction 
enzyme analyses and sequencing with 5’ AOX and  ’ 
AOX universal primers. The HindIII enzyme was 
used for restriction enzyme analysis, which cut the 
recombinant vector at two specific sites, resulting in 
two fragments with a size of approximately 1250 bp 
and 3650 bp (Figure 3). 
Screening of recombinant P. pastoris strains: In 
order to obtain highest possible multiple copies of the 
expression cassette in P. pastoris strain x33, the 
concentration of Zeocin increased up to 2000 μg/ml 
according to supplier’s instructions (Easy Select 
Pichia Expression manual, Invitrogen). In these 
criteria, transformants containing multiple copies of 
vectors integrated into the host genome were only able 
to grow on. Approximately six transformants of X33 
strains survived in high concentration of the antibiotic 
and they were screened for the integrative plasmid by 
P R using 5’AOX1 and  ’AOX1 primers.  he 
positive PCR colonies were then transferred into the 
expression medium for analyzing protein expression 
profiles. 
Intracellular expression analysis: Following the 
induction of the LmSTI1 protein with methanol in the 
BMMY medium, the X33 cells were harvested and the 
total intracellular proteins were extracted using the 
breaking buffer and glass beads. Protein 
electrophoresis (SDS-PAGE) was performed and the 
expected ~67 KD band (the 62.1 KD protein of 
interest plus 5 KD peptide sequence for detection and 
purification of the protein) was visualized on 
12% SDS-PAGE gel (Figure 4). Results from this 
study indicated that there is no similar band in the X33 
negative control. The position of the protein on the gel 
was also confirmed by western blotting analysis using 
antibodies against LmSTI1 protein and HRP-
conjugated mouse anti IgG as primary and secondary 
antibodies, respectively (Figure 5). The level of 
 
 
Figure 3. Restriction analysis of PICZ-LmSTI1. M, marker; 1, 
recombinant plasmid; 2, vector digested by HindIII enzyme that 







Figure 4. SDS-PAGE of intracellular protein extracted from X-
33. Lane 1, uninduced sample; lane 2, induced sample; lane M, 
prestained molecular-weight marker, arrow indicates LmSTI 




Figure 5. Western-blot analysis of the LmSTI1 protein expressed 
in P. pastoris. Lane M, prestained molecular-weight marker; 
Lane 1, here is X33 transformed by only pPICZA vactor (without 
lmsti1 gene); Lane 2, induced sample. 
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expression was 0.2% of total proteins when estimated 
by a densitometric scan (ImageJ software) of the 
SDS-PAGE and Western blotting. 
Discussion 
E. coli offers several advantages for recombinant 
protein expression, including low cost, rapid growth 
rate and high protein yields. However, there are 
limitations including the lack of post-translational 
modification, presence of endotoxin and insolubility, 
as well as aggregation of certain proteins as inclusion 
bodies
28
. Additionally, mammalian cells (e.g., 
Chinese hamster ovary cells) suffer from high cost 
and more complex nutritional requirements. In the 
last decades, P. pastoris has proved to be a 
potentially powerful expression system to produce 
recombinant proteins
29,30
. P. pastoris has the ability 
to grow on minimal medium, prepare all criteria 




In this study, LmSTI1 was intracellularly expressed in 
P. pastoris strain X33. Webb JR et al. previously 
expressed such protein in two different systems pQE 
and pET in E. coli, showing inclusion bodies and 
more procedures such as solubilization and 
refolding
17,32
. In this study, the pPICZA shuttle 
vector was used to express the protein in the yeast. In 
this regard, the lmsti1 gene was inserted downstream 
of the strong promoter AOX1 immediately after the 
initiation codon ATG in a KOZAK sequence. The 
recombinant vector was subsequently transformed 
into the yeast. It is well-known that integration into 
the genome limits gene copy numbers. This was 
resolved by increased zeocin concentrations to 2000 
µg/ml, leaving only one to ten colonies when 
compared to the lower concentration of Zeocin, 100 
µg/ml. These recombinant colonies were then chosen 
for protein expression.  
When supernatants and cell pellets were assessed 
after cell lysis, it turned out that most proteins were 
intracellulary expressed in yeast
33
, resulting in the 
soluble recombinant protein with no aggregation. 
Moreover, because there was no signal sequence in 
the pPICZA vector, the protein was not observed out 
of the cells (data not shown). As shown in SDS-
PAGE and Western blotting (Figures 4 and 5), the 
protein size increased from 62.1 KD to about 67 KD, 
due to addition of other sequences such as His-Tag 
and c-myc. 
The optimum criterion for expression was found in the 
buffered complex medium (e.g, BMMY) three days 
after induction by purified methanol at a final 
concentration of 0.5%. Because protein expression 
was performed in buffered media, the PH of the media 
seems to exhibit no effects on protein production. 





phenotype superior, but not mut
s
, could successfully 
express our protein (data not shown); however, the 
mut
s
 phenotype was preferred by some researchers
36,37
. 
Despite the lower expression level (0.2% of TSP), the 
protein band was detected in SDS-PAGE and Western 
blotting. Nowadays, codon optimization is one suitable 
approach to increase gene expression in yeasts
38
. Some 
studies demonstrated that codon optimization could 
improve malaria gene expression in P. pastoris
39,40
. 
Anjali Yadava et al. showed that Plasmodium 
falciparum F2 domain expression in P. pastoris, based 
on the pichia codon usage, improved nine-fold 
compared to that in E. coli- based codon usage, which 
itself expressed that protein four-fold more than native 
F2 domain in E. coli. Furthermore, proteins produced 
in Pichia- based codon usage could be detected by 
Coomassie blue staining, Western blotting and ELISA, 
while the native protein failed to be detected when 
expressed in P. pastoris
41
. Therefore, it might be 
possible to improve protein expression levels by 
pichia codon optimization. 
Whole recombinant yeast vaccine is an appropriate 
method to elicit cellular immune responses against 
intracellular microorganisms, offering potential 
advantages including intrinsic adjuvant property, 
safety, protein purification elimination and increased 
MHC class I and II expression on antigen processing 
cells
19
. Based on this system, the protein LmSTI1 was 
cloned and expressed in yeast P. pastoris to use in 
vaccination. To our knowledge, this is the first report 
of the cloning and expression of the lmsti1 gene in 
yeasts. Some reports showed that a low amount of 
protein against E.G7-OVA tumor cells, and even as 
few as 2 ng  human immunodeficiency virus Gag 
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Conclusion 
Taken  together, whole yeast vaccine might be one of 
the best strategies, because of safety, ease of 
production and the lack of downstream processes. In 
the future, we will evaluate whole yeast vaccine 
expressing LmSTI1 against cutaneous leishmaniasis 
in animal models. 
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